Lin and colleagues reported dual-functional PLGA-ICG-R848 NPs in combination with PTT and immunotherapy for prostate cancer (PCa), promoting BMDCs maturation with the considerably increased proportions of CD11c+CD86+ and CD11c+CD80+ cells [152]. This evidence concerns the gene ITGAX and prostate carcinoma.